(19)-3s

N/A

Report date: 2026/03/19 16:57:34

Base Information

Drug Name(19)-3s

Drug Alias Nameanti-CD19-Fab2/CD3scFv bispecific antibody (Immunomedics)anti-CD3/anti-CD19 bispecific T-cell engager (Immunomedics)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsB-lymphocyte antigen CD19 modulators

TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesImmunomedics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunomedics Inc

Active IndicationsN/A

Inactive IndicationsLymphoma

Other Information

ATC CodeN/A